Arctic Bioscience H1 2021 results: phase IIb study on track and revenue up 50% y/y
Arctic Bioscience AS (“Arctic Bioscience” or “the company”) today announces its results for the first half 2021. Highlights · Successful private placement and IPO raising NOK 300 million, with first day of trading on Euronext Growth on 24 February 2021 · On track and on budget for phase IIb clinical study on HRO350 in mild-to-moderate psoriasis, planned start H1 2022 · Financial strength to execute on ongoing development programs, invest in new production facility and capacity to participate in new selected pre-clinical trials · Revenue increased 50% y/y driven by